Gilead Sciences Forecast, price target & analysts
Gilead Sciences Target price 2026 - Analyst rating & recommendation
Gilead Sciences Classifications & Recommendation:
Gilead Sciences Price Target
| Target Price | $137.70 |
| Price | $121.60 |
| Potential | 13.24% |
| Number of Estimates | 30 |
| 30 Analysts have issued a price target Gilead Sciences 2027 . The average Gilead Sciences target price is $137.70. This is 13.24% higher than the current stock price. The highest price target is $160.65 32.11% , the lowest is $106.05 12.79% . | |
| A rating was issued by 37 analysts: 29 Analysts recommend Gilead Sciences to buy, 8 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Gilead Sciences stock has an average upside potential 2027 of 13.24% . Most analysts recommend the Gilead Sciences stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
31 Analysts have issued a sales forecast Gilead Sciences 2025 . The average Gilead Sciences sales estimate is $29.8b . This is 2.44% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $31.2b 7.28% , the lowest is $28.0b 3.63% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $28.8b | 6.04% |
|---|---|---|
| 2025 | $29.8b | 3.63% |
| 2026 | $30.7b | 3.10% |
| 2027 | $32.3b | 4.98% |
| 2028 | $33.6b | 4.26% |
| 2029 | $35.2b | 4.54% |
| 2030 | $36.8b | 4.65% |
| 2031 | $37.4b | 1.73% |
| 2032 | $37.1b | 0.80% |
31 Gilead Sciences Analysts have issued a net profit forecast 2025. The average Gilead Sciences net profit estimate is $10.3b . This is 27.50% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $11.0b 35.56% , the lowest is $9.8b 20.82% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $480m | 91.53% |
|---|---|---|
| 2025 | $10.3b | 2,054.27% |
| 2026 | $11.0b | 6.51% |
| 2027 | $11.8b | 6.80% |
| 2028 | $12.8b | 8.56% |
| 2029 | $14.0b | 9.50% |
| 2030 | $15.2b | 8.66% |
| 2031 | $15.8b | 4.27% |
| 2032 | $15.9b | 0.54% |
Net Margin
| 2024 | 1.67% | 92.01% |
|---|---|---|
| 2025 | 34.70% | 1,978.67% |
| 2026 | 35.85% | 3.31% |
| 2027 | 36.47% | 1.73% |
| 2028 | 37.98% | 4.14% |
| 2029 | 39.78% | 4.74% |
| 2030 | 41.30% | 3.82% |
| 2031 | 42.33% | 2.49% |
| 2032 | 42.90% | 1.35% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
31 Analysts have issued a Gilead Sciences forecast for earnings per share. The average Gilead Sciences EPS is $8.33 . This is 28.95% higher than earnings per share in the financial year 2024. The highest EPS forecast is $8.85 37.00% , the lowest is $7.89 22.14% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $0.38 | 91.56% |
|---|---|---|
| 2025 | $8.33 | 2,092.11% |
| 2026 | $8.87 | 6.48% |
| 2027 | $9.47 | 6.76% |
| 2028 | $10.28 | 8.55% |
| 2029 | $11.26 | 9.53% |
| 2030 | $12.23 | 8.61% |
| 2031 | $12.76 | 4.33% |
| 2032 | $12.82 | 0.47% |
P/E ratio
| Current | 18.82 | 98.20% |
|---|---|---|
| 2025 | 14.61 | 22.38% |
| 2026 | 13.71 | 6.16% |
| 2027 | 12.84 | 6.35% |
| 2028 | 11.83 | 7.87% |
| 2029 | 10.80 | 8.71% |
| 2030 | 9.94 | 7.96% |
| 2031 | 9.53 | 4.12% |
| 2032 | 9.48 | 0.52% |
Based on analysts' sales estimates for 2025, the Gilead Sciences stock is valued at an EV/Sales of 4.75 and an P/S ratio of 5.06 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 4.87 | 2.96% |
|---|---|---|
| 2025 | 4.75 | 2.48% |
| 2026 | 4.61 | 3.01% |
| 2027 | 4.39 | 4.74% |
| 2028 | 4.21 | 4.09% |
| 2029 | 4.03 | 4.34% |
| 2030 | 3.85 | 4.45% |
| 2031 | 3.78 | 1.71% |
| 2032 | 3.81 | 0.81% |
P/S ratio
| Current | 5.19 | 25.15% |
|---|---|---|
| 2025 | 5.06 | 2.38% |
| 2026 | 4.91 | 3.01% |
| 2027 | 4.68 | 4.74% |
| 2028 | 4.49 | 4.09% |
| 2029 | 4.29 | 4.34% |
| 2030 | 4.10 | 4.45% |
| 2031 | 4.03 | 1.70% |
| 2032 | 4.06 | 0.80% |
Gilead Sciences...
Current Gilead Sciences Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Dec 12 2025 |
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Dec 10 2025 |
| Scotiabank |
➜
Sector Outperform
|
Initiated | Nov 13 2025 |
| Needham |
Buy
➜
Buy
|
Unchanged | Nov 13 2025 |
| Truist Securities |
Buy
➜
Buy
|
Unchanged | Nov 03 2025 |
| RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Oct 31 2025 |
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Oct 31 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Dec 12 2025 |
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Dec 10 2025 |
|
Initiated
Scotiabank:
➜
Sector Outperform
|
Nov 13 2025 |
|
Unchanged
Needham:
Buy
➜
Buy
|
Nov 13 2025 |
|
Unchanged
Truist Securities:
Buy
➜
Buy
|
Nov 03 2025 |
|
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Oct 31 2025 |
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Oct 31 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
